A Phase 2 Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Active Psoriatic Arthritis
Latest Information Update: 12 Jun 2025
At a glance
- Drugs Lutikizumab (Primary) ; Risankizumab (Primary)
- Indications Psoriatic arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors AbbVie
Most Recent Events
- 09 Apr 2025 Status changed from not yet recruiting to recruiting.
- 17 Mar 2025 Planned initiation date changed from 18 Apr 2025 to 30 Jun 2025.
- 11 Mar 2025 New trial record